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Effect of a new model of hemodialysis potassium removal on the control
of ventricular arrhythmias. The primary aim of this multicenter, prospec-
tive, randomized cross-over study was to clarify whether a new model of
hemodialysis (HD) potassium (K) removal using a decreasing intra-HD
dialysate K concentration and a constant plasma-dialysate K gradient
(treatment B) is capable of reducing the arrhythmogenic effect of standard
HD, which has a constant dialysate K concentration and decreasing
plasma-dialysate K gradient (treatment A). The secondary aim was to
verify whether this new model is clinically safe. In treatment B, the initial
dialysate K concentration had to be 1.5 mEq/liter less than the plasma K
concentration, and exponentially decrease to 2.5 mEq/liter at the end of
HD. Forty-two chronic HD patients with an increase in premature
ventricular complexes (PVC) during dialysis were enrolled from 18
participating centers, and randomly assigned to either sequence 1 (ABA)
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or sequence 2 (BAB). A pool of 333 of 378 expected ECG loIter
recordings were checked for signal quality; 269 (71%) from 36 patients
(86%) had a satisfactory signal quality and 108 were selected for analysis
(1 per patient per period). There was a difference in the natural logarithm
of the increase in PVC/hr and PVC couplets/hr during HD between
treatments A and B (1.70 1.59 vs. 1.09 1.76 and 0.94 0.86 vs. 0.64
1.01, a reduction of 36% and 32%, P = 0.011 and 0.047, respectively)
without any carry over effect (P = 0.61 and 0.24, respectively). The fact
that this decrease of one third is due to a lower plasma-dialysate K
gradient is supported by the observation that it was more evident during
the first than the last two hours of HD (a reduction in the natural
logarithm of the increase in PVC/hr and PVC couplets/hr of 60% and
60%, P 0.002 and 0.009, vs. 26% and 17%, P = 0.098 and 0.332,
respectively): the initial plasma-dialysate K gradient was 2.3 times lower
during treatment B than during treatment A, without adversely affecting
pre-HD plasma K levels. These results could have a considerably clinical
impact not only because of the possibility of physiologically decreasing the
arrhythmogenic effect of HD, but also because this effect can be consid-
ered a "marker" of the electrophysiological derangement induced by the
administration of standard HD three times a week for years ("electric
disequilibrium syndrome").
Given selective cell permeability to potassium (K), the resting
electric membrane potential (REMP) of most cells is related to
the diffusive passive fluxes of K ions [1—3]. The level of REMP
affects cell excitability: the greater the difference between REMP
and the threshold level of the electric potential, the longer the
depolarization time.
In chronic hemodialysis (HD) patients, intradialysis K is re-
moved by diffusion throughout the HD membrane, according to
the concentration gradient between plasma and dialysate K levels.
With constant dialysate K levels, this gradient decreases rapidly
during the first hour of HD and slowly in the following hours. The
diffusive fluxes of K through the HD membrane produce diffusive
passive fluxes through the membrane cells, with greater negativ-
ization of REMP and, consequently, less cell membrane excitabil-
ity. This phenomenon is more evident during the first hour of HD,
when the plasma-dialysate K gradient is higher, and in the cells in
which REMP is more dependent on diffusive K fluxes.
Cardiac electrophysiology is related to the activity of cells that
are variably affected by diffusive K fluxes [41. The changes in K
fluxes induced by HD may therefore influence cardiac cell elec-
trophysiology, and cardiac arrhythmias may arise [5,6]. There is
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no general agreement about the arrhythmogenic effect of HD
[7—9]. Hypokaliemia and hyperkaliemia are well known conditions
affecting cardiac rhythm [10], and we therefore believe that the
kinetics of K during HD may be an important cause of intradi-
alysis arrhythmias [7]. The use of high dialysate K concentrations
reduces the increase in arrhythmias but does not allow adequate
K removal, whereas the use of concentrations capable of ensuring
a small and steady concentration gradient throughout the HD
membrane could satisfy this requirement.
This multicenter prospective, randomized, controlled study was
designed to verify this hypothesis. The primary aim was to clarify
whether a new model of HD K removal, with dialysate K
concentrations being reduced during HD in order to maintain the
same K gradient between plasma and dialysate, is capable of
reducing the arrhythmogenic effect of standard HD, during which
the dialysate K concentration remains constant and there is a
decreasing gradient between plasma and dialysate. The secondary
aim of this study was to verify whether this new model of HD K
removal is clinically safe.
The arrhythmogenic effect of HD was considered not only
because of its still discussed clinical importance, but also because
it is a "marker" of the electrophysiological status of the cells of
uremic patients, which are greatly modified during standard HD
treatment three times a week for many years.
Methods
Patients
Uremic patients on stable HD treatment were recruited from
the 18 participating Centers. After they had given their oral
consent, the patients fulfilling the entry criteria were selected for
the experimental phase.
Inclusion criteria
Patients aged more than 18 years, who had been on chronic
thrice-weekly HD for at least six months, and who were in stable
clinical condition were admitted to the study. The continuous 24
hours electrocardiographic (ECG) recording made on the HD day
had to satisfy one of the following conditions: (a) if the inter-
dialysis number of premature ventricular complexes (PVC)/hr was
less than two, at least a fourfold increase in their number during
HD and the subsequent four hours; or (b) if the inter-dialysis
number of PVC/hr was two or more, at least a twofold increase in
their number during HD and the subsequent four hours. The
"inter-dialysis time" was defined as the recording time excluding
the time of MD and the subsequent four hours.
Exclusion criteria
Patients on antiarrhythmic treatment or receiving pace-maker
cardiac stimulation, those whose dosage of digitalis was unstable,
and those requiring dialysate K concentrations of more than 3
mEq/liter were excluded from the study.
Hemodialysis
The patients had to undergo HD at the same time of day for
both treatments in order to avoid any interference with the
circadian rhythms of arrhythmia [11]. For each patient, the
decrease in intra-dialysis body wt and the dose of oral sodium
bicarbonate and/or sodium polystyrene suiphonate therapy had
not to change during the study. In the same patient and through-
out the three weeks of the study, only the concentration of
dialysate K could change, and then only in accordance with the
study protocol.
Twenty-four hour EGG recordings
On the HD day, continuous 24-hour EGG recording was started
at least four hours before HD and lasted until at least four hours
after the end of the HD session. Three 24-hour recordings were
made per week, with a total of nine recordings for each patient.
The 24-hour EGG signal was recorded on an LP 103 system
(Remco Italia Cardioline), and the tapes were centrally analyzed
for ventricular arrhythmias by means of a semiautomatic system at
the Department of Biomedical Engineering of the Milan Poly-
technic University under cardiological supervision. The readers
were blinded as to treatment.
Treatment definitions
Treatment A. Standard HD with a constant dialysate K concen-
tration of no more than 3 mEq/liter and a consequently decreasing
plasma-dialysate K gradient.
Treatment B. Experimental HD with an exponentially decreas-
ing dialysate K concentration. The initial concentration had to be
1.5 mEq/liter less than the plasma K concentration and decrease
to 2.5 mEq/liter at the end of the HD session. Thus, the
plasma-dialysate K concentration gradient during treatment B
was expected to be constant, with a consequently more constant
intradialysis K removal rate.
All of the HD sessions were performed using a Fresenius 2008
E machine modified for K modeling.
Study protocol
The study was carried out according to a multicentre cross-over
design of three weeks with two treatments (A or B), two se-
quences (sequence 1 = ABA and sequence 2 = BAB), and three
adjacent periods of one week (periods 1, 2 and 3). The patients
were centrally randomized to one of the two sequences according
to a balanced block randomization list stratified by Center. The
choice of the cross-over experimental design was suggested by the
between and within-patient sources of variance of the natural
logarithm of the number of PVC/hr. This analysis was made using
data relating to the frequency of PVC/hr evaluated on the basis of
three consecutive 24-hour ECG recordings in 15 clinically stable
patients with various cardiac disorders [12]. The within-patient
variance was only 18% of the total variance, thus suggesting that
a cross-over study [13—16] would be more efficient than a classical
parallel group study. A 12-month recruitment period was esti-
mated.
Sample size calculation
The sample size was calculated by considering the difference in
the natural logarithm of the increase in PVC/hr during HD
between treatment A and B as the primary response variable of
the study. An estimate of the within-patient variability of this
natural logarithm was obtained using the data of Morganroth and
Michelson [12]. The calculated sample size of 40 patients was
based on: a significance level (a error) of 0.05; a /3 error of 0.2; a
power [1-/3] of 0.8; a reduction in the natural logarithm of PVC/hr
with treatment B in comparison with treatment A equal to 50% of
the variability of the phenomenon; a two tailed paired t-test for
both a and /3 errors; and a drop-out rate of 20%.
Pre-dialysis Dialysis Post-dialysis Analysis
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Calculation of the response variables and types of analysis
The number of PVC/hr and PVC couplets/hr, which are clini-
cally easier to understand than logarithmic values, are not nor-
mally distributed variables because of their large positive skew-
ness. We thus chose their natural logarithm transformations (L)
because these have the statistical properties of being normally
distributed variables, and consequently make it possible to use the
powerful technique of the analysis of variance. The following steps
were adopted for the calculation of the response variables: (a)
calculation of the natural logarithm of (PVC/hr+ 1); the one is
added because of the possibility of a number of PVC/hr equal to
zero and the consequent impossibility of managing its logarithm;
(b) calculation of the difference [ln(PVC/hr+ l)postI — [ln(PVC/
hr+ 1)prc], which equals ln[(PVC/hr+ 1)05/(PVC/hr+ 1)pre]
(henceforth called LPVC). In this formula, the subscript pre refers to
the mean value of the four hours before HD and the subscript post
refers to the mean value of the HD session (analysis A), or the
mean value of each two hour gap of HD and post-HD time
(analysis B), as illustrated in Figure 1. The second response
variable, ln[(PVC couplets/hr+ 1)05/(PVC couplets/hr+ 1)prel
(henceforth called LPVCC) was analyzed using the same two
types of analyses.
Clinical relevance of LPVC and LPVCC after exponential
transformation
If a HD session has no arrhythmogenic effect, the expected
values of LPVC and LPVCC would be zero; they progressively
increase in proportion to the arrhythmogenic effect. If the exper-
imental treatment (treatment B) decreases these values in com-
parison with standard treatment (treatment A), we can conclude
that the first is less arrhythmogenic than the second.
In clinical terms, after the exponential transformation of LPVC
and LPVCC, we obtain the increase in the number of PVC/hr and
PVC couplets/hr during HD and thus the percentage reduction in
these variables with treatment B in comparison with treatment A
clinically quantifies its effect.
0 ——
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Fig. 2. Descriptive trend analysis (25t5, 5tyh and percentiles) of heart
rate (upper panel), the number of premature ventricular complexes/hr (PVC!
hr; middle panel) and the number of premature ventricular complex cou-
plets/hr (PVC couplets!hr; lower panel) in the four hours before, during and at
the eight hours after dialysis. The vertical reference lines indicate the first
and the last hour of dialysis. Unlike the maximum heart rate values, the
maximum values of PVC/hr and PVC couplets/hr occurred before the end
of dialysis. Symbols are: (....,.,.,) P75; (u.) P50; (.) P25.
Holter recording selection
Some of the 24-hour Holter recordings were considered totally
unsuitable for analysis because of the bad quality of the ECG
signal (presence of superimposed noise, incorrect positioning of
the electrodes) and the consequent inability to distinguish normal
beats from pathological PVCs. The bad signal quality was some-
times present during only a part of some of the recordings, leading
to temporary gaps in which the PVCs could not be detected. In
these cases, because of the wide variability in the number of
PVC/hr suggested by the study of Morganroth and Michelson
[12], only the recordings with a satisfactory signal quality lasting
for a total of at least two hours during the four hours before HD,
during HD session itself and during the four hours after the end
of the session were selected for analysis.
Given the possibility that there would be a different number of
valid recordings for each patient in each period, the protocol
foresaw one ECG recording per patient per period. As the
a — —
—
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Fig. 1. Time sampling protocol and types of analysis. In all of the analyses,
the four hours before dialysis (pre-dialysis) were considered as baseline.
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PVC/hr
Fig. 3. Descriptive trend analysis (50th and 75"
percentiles) of the number of premature
ventricular complexes/hr (PVC/hr) by sequence
and period in the four hours before, during and at
eight hours after dialysis. The vertical reference
lines indicate the first and the last hour of
dialysis. The effect of treatment B was evident
not only in the reduction in PVC/hr during and
after dialysis as a whole (sequence 2; lower
panel), but also in the specific reduction in
PVC/hr in the first two hours of dialysis
(sequence 1; upper panel).
interval between the HD sessions was not always the same, we
tried to select the three recordings made on the same day of each
week, the choice of the day being conditioned by the fact that,
when the patients were on the treatment B, the plasma-dialysate
gradient concentration had to be less than 2 mEq/liter (the
expected value was 1.5 mEq/liter). When there were suitable ECG
recordings on different days of the week for all of the three
treatment periods, the earliest day in the week was chosen. When
only ECG recordings made on different days in each treatment
period were available, any three were included in the analysis
providing there was at least one for each period. If a patient did
not have even one valid ECG recording for one of the periods,
he/she was excluded from the analysis.
Statistical analysis
The descriptive analysis is based on the percentile distributions
of the variables not normally distributed (such as the number of
PVC/hr and PVC couplets/hr), and mean values SD for normally
distributed continuous variables (such as LPVC and LPVCC,
considered the main response variables of the study). The main
statistical analysis was carried out according to the model of the
analysis of variance for a cross-over design with two sequences,
two treatments and three periods, using unique sums of squares
and treatment A as reference. The assumption of normality of the
error term required by this model was tested using the analysis of
residuals. A probability value of less than 0.05 was considered to
be statistically significant. The statistical analyses were made using
the software program SPSS for Windows, Release 6.01.
Results
General
Between January 1993 and October 1994, 2,207 uremic patients
on HD treatment were recruited in the 18 participating Centers.
Forty-two of these (2%) satisfied the entry criteria and gave their
oral consent, and were thus selected for the experimental phase
and randomized to sequence 1 (ABA 21 patients) or sequence 2
(BAB 21 patients). Six of these patients (3 from sequence 1 and 3
from sequence 2) were excluded from the analysis because of the
poor quality of the ECG signals of all of the recordings made in
Sequence 1 (ABA)
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Table 1. Mean values and SD of LPVC and LPVCC (analysis A) in sequence by period and treatment groups
Sequence
Treatment
1 (ABA) 2 (BAB)
1
Period
2 3 A
Treatment
B % red. 1
Period
2 3
Treatment
A B % red. A B % red. P value
LPVC
Mean 1.16 0.50 1.41 1.29 0.50 (61) 1.41 2.11 1.93 2.11 1.67 (21) 1.70 1.09 (36) 0.011
SD 1.88 1.86 1.83 1.86 1.86 1.64 1.32 1.67 1.32 1.66 1.59 1.76
LPVCCb
Mean 0.91 0.43 0.77 0.84 0.43 (49) 0.71 1.03 0.98 1.03 0.85 (18) 0.94 0.64 (32) 0.047
SD 1.24 1.15 1.12 1.18 1.15 0.88 0.53 0.86 0.53 0.87 0.86 1.01
The numbers in brackets are the % reductions in the response variables from treatment A to treatment B. The overall reduction is 36% and 32%
respectively.
a LPVC, natural logarithm of the increase in PVC/hr during HD in respect to baseline
b LPVCC, natural logarithm of the increase in PVC couplets/hr during HD in respect to baseline
Table 2. Mean values and SD of LPVC and LPVCC (analysis B) in sequence by period and treatment groups
Sequence
Treatment
1 (ABA) 2 (BAB)
1
Period
2 3 A
Treatment
B % red. 1
Period
2 3 A
Treatment
B % red. A B % red. P value
First 2 hr of dialysis
LPVC
Mean 0.95 —0.17 0.84 0.90 —0.17 (119) 0.97 1.80 1.51 1.80 1.24 (31) 1.35 0.54 (60) 0.002
SD 1.81 1.61 1.68 1.75 1.61 1.52 1.35 1.63 1.35 1.58 1.55 1.60
LPVCC
Mean 0.72 0.02 0.46 0.59 0.02 (97) 0.51 0.95 0.68 0.95 0.60 (37) 0.77 0.31 (60) 0.009
so 1.26 1.10 1.08 1.17 1.10 0.83 0.67 0.93 0.67 0.88 0.92 0.99
Last 2 hr of dialysis
LPVC
Mean 1.16 0.65 1.50 1.33 0.65 (51) 1.55 2.08 2.19 2.08 1.87 (10) 1.71 1.26 (26) 0.098
SD 2.04 2.19 2.06 2.05 2.19 1.74 1.62 1.70 1.62 1.72 1.84 1.96
LPVCC
Mean 0.98 0.60 0.93 0.96 0.60 (38) 0.78 0.95 1.19 0.95 0.99 (—4) 0.96 0.80 (17) 0.332
SD 1.27 1.35 1.21 1.24 1.35 1.03 0.72 0.90 0.72 0.97 0.98 1.16
First 2 hr after dialysis
LPVC
Mean 1.34 1.10 1.13 1.24 1.10 (11) 1.36 1.51 1.69 1.51 1.53 (—1) 1.38 1.32 (4) 0.780
SD 2.00 1.38 1.39 1.70 1.38 1.85 1.79 1.69 1.79 1.77 1.75 1.58
LPVCC
Mean 0.87 0.74 0.74 0.81 0.74 (9) 0.77 0.61 0.94 0.61 0.86 (—41) 0.71 0.80 (—13) 0.513
SD 1.25 0.99 0.99 1.12 0.99 1.07 0.94 0.96 0.94 1.02 1.03 1.01
Second 2 hr after dialysis
LPVC
Mean 0.75 0.48 0.28 0.52 0.48 (8) 0.50 1.25 1.47 1.25 0.99 (21) 0.89 0.74 (17) 0.505
SD 2.02 1.31 1.52 1.77 1.31 2.10 1.66 1.64 1.66 1.87 1.72 1.59
LPVCC
Mean 0.59 0.39 0.36 0.48 0.39 (19) 0.20 0.58 0.91 0.58 0.56 (4) 0.53 0.48 (9) 0.672
SD 1.21 0.90 1.01 1.11 0.90 1.25 0.85 0.86 0.85 1.06 0.98 0.98
The numbers in brackets are the % reductions in the response variables from treatment A to treatment B. With treatment B, there is a significant
reduction of 60% in both response variables only during the first 2 hours of dialysis.
one or more of the three treatment periods. Thus, 36 patients ECG recordings
(86%, 25 males and 11 females) on a thrice weekly HD schedule A pool of 333 of the expected 378 ECG Holter recordings was
for a median of 52 months (25th and 75th percentiles of 20 and 90 checked for signal quality; 269 of these (71%) from 36 patients
months, respectively) were analyzed. The median age of the (86%) had a satisfactoty signal. One hundred and eight ECG
patients was 67 years (25°' and 75°' percentiles of 61 and 72 years, recordings were chosen for the full statistical analysis according to
respectively). HD treatment lasted for 3.6 0.6 hours. Cu- the selection criteria described above.
prophane was used as the membrane in 20 patients and bicarbon-
ate buffer in 28 patients. The blood flow rate was 325 46 mi/mm Response variables
and the dialysate flow rate 500 ml/min. The filter surface area was A descriptive trend analysis of heart rate, the number of
1.4 0.4 m2. PVC/hr and the number of PVC couplets/hr in the four hours
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and a reduction of 32%, P = 0.047). A direct treatment effect was
present without any carry-over effect for both variables (P =0.61
and 0.24, respectively). The effect of treatment B in decreasing
these variables is also evident in the period by sequence box plots
(Fig. 4). In analysis B (Table 2), treatment B significantly de-
creased these variables only in the first two hours (1.35 vs. 0.54, a
difference of 0.81 and a reduction of 60%, P = 0.002 and 0.77 vs.
0.31, a difference of 0.46 and a reduction of 60%, P = 0.009).
The increases in the number of PVC/hr and PVC couplets/hr
during HD are shown in Table 3, which illustrates the exponen-
tialized means of LPVC and LPVCC. In comparison with treat-
ment A, treatment B reduced the increase in the number of
PVC/hr and PVC couplets/hr during HD by 5.95 to 3.58 times and
2.56 to 1.95 times, respectively (a difference of 2.37 and a
reduction of 40%; and a difference of 0.61 and a reduction of
24%, respectively). In sequence 1, which included patients who
were less arrhythmic before HD than those in sequence 2, the
effect of treatment B was greater for both exponentialized vari-
ables (55 vs. 33% and 34 vs. 16%, respectively).
Frequency of hypotension
The frequency of intradialysis symptomatic hypotension was 11
out of 108 HD sessions (10%) and did not change with treatment.
Biochemical results
Fig. 4. Effect of treatment B (analysis A) in decreasing LPVC (upper panel)
and LPVCC (lower panel) in sequence by period group box plots. Symbols are
(LI) period 1; (Ill) period 2; () period 3.
before, during and at eight hours after HD is shown in Figure 2.
Heart rate increased during HD, reached maximum values one
hour after the end of the HD session and returned to baseline
values only eight hours after the end of the session. Conversely,
the maximum values of PVC/hr and PVC couplets/hr were
reached before the end of HD. On average, the patients in
sequence 1 were less arrhythmic before HD than those in
sequence 2 (6.0 vs. 9.1 PVC/hr and 3.2 vs. 4.5 PVC couplets/hr,
respectively). A descriptive trend analysis of the number of
PVC/hr by sequence and period in the four hours before, during
and at eight hours after HD is shown in Figure 3. The effect of
treatment B was evident not only in the reduction in PVC/hr
during and after HD as a whole (see sequence 2), but also in the
specific reduction observed during the first two hours of HD (see
sequence 1).
The mean values and SD of LPVC and LPVCC in sequence by
period groups are shown in Tables I (analysis A) and 2 (analysis
B). The assumption of normality of the error term for these
response variables was satisfied after being tested using the
analysis of residuals (data not shown). From treatment A to
treatment B, analysis A (Table 1) revealed a significant decrease
in these variables (1.70 vs. 1.09, a difference of 0.61 and a
reduction of 36%, P = 0.011, and 0.94 vs. 0.64, a difference of 0.30
The mean values and SD of predialysis plasma, dialysate and
plasma-dialysate gradient K concentrations in sequence by period
groups are shown in Table 4. There were no differences in
predialysis plasma K levels between treatments A and B (5.48 vs.
5.46 mEq/liter, P = 0.717); conversely, the baseline plasma-
dialysate K gradient was 2.3 times higher on treatment A than on
treatment B (2.85 vs. 1.26 mEq/liter, P < 0.001). The intradialysis
plasma-dialysate K gradient concentration (Fig. 5) was constant
during treatment B (period 2 in sequence 1 and periods 1 and 3 in
sequence 2) and exponentially decreased during treatment A
(periods 1 and 3 in sequence 1 and period 2 in sequence 2). A
specular trend was evident for dialysate K concentrations. In 13 of
the 108 HD sessions (12%), a pre-HD plasma K value  6.5
mEq/liter was observed, with a value  7.0 mEq/liter in three.
Eight of these 13 observations were made after a previous period
on treatment A (11% of 72 HD sessions) and 5 after treatment B
(14% of 36 HD sessions). The three cases of hyperkaliemia  7
mEq/liter were all observed after a previous period on treatment
A. Hyperkalemia was observed during the first HD of the week in
three of the 13 observations (23%) instead of the expected value
of 33%. There was no difference in the pre- and intra-HD profile
of any of the plasma K concentration values between the three
HD sessions of the week (data not shown). Sodium, total and
ionized calcium, phosphate, bicarbonate, pH, pCO2, hematocrit
and total plasma protein levels did not show any particular
treatment-related pre- or intra-HD pattern (data not shown).
Discussion
The results of this study clearly demonstrate that the use of a
new model of HD potassium removal is capable of reducing the
arrhythmogenic effect of standard HD in chronic uremic patients
prone to this complication. This decrease was statistically and
clinically significant for both LPVC and LPVCC (36% and 32%,
respectively). This effect was most striking during the first two
hours of HD, according to the fact that the two treatments mainly
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Table 3. Exponentialized mean values of LPVC and LPVCC in sequence by period and treatment groups
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Sequence
A
Treatment
B % red.
1 (ABA) 2 (BAB)
1
Period
2 3 A
Treatment
B % red. 1
Period
2 3
Treatment
A B % red.
Increase in PVC/hr'
Increase in PVC couplets/hr"
3.19
2.48
1.65 4.10
1.54216
3.65
2.32
1.65 (55)
1.54 (34)
4.10
2.03
8.25
2.80
6.89
2.67
8.25
2.80
5.50 (33)
2.35 (16)
5.95
2.56
3.58 (40)
1.95 (24)
These values indicate the fold-increase in the number of PVC/hr and PVC couplets/hr during hemodialysis in comparison with baseline. The numbers
in brackets are the % reductions in the increases in PVC/hr and PVC couplets/hr during dialysis from treatment A to treatment B. Treatment B reduced
the increase in the number of PVC/hr and PVC couplets/hr by 40% and 24%, respectively.
a Increase in PVC/hr = exponential of mean value of LPVC
b Increase in PVC couplets/hr = exponential of mean value of LPVCC
Table 4. Mean values and SD of plasma, dialysate and plasma-dialysate K concentrations at the start of dialysis in sequence by period and
treatment groups
Sequence
Treatment
1 (ABA) 2 (BAB)
Period Treatment Period Treatment
1 2 3 A B Total 1 2 3 A B Total A B P value
Plasma K concentration mEq/liter
Mean 5.59 5.59 5.67 5.63 5.59 5.61 5.21 5.33 5.45 5.33 5.33 5.33 5.48 5.46 0.717
SI) 1.02 0.84 0.92 0.97 0.84 0.91 0.64 0.58 0.58 0.58 0.61 0.60 0.78 0.73
Dialysate K concentration mEq/liter
Mean 2.60 4.08 2.45 2.53 4.08 3.31 3.37 2.08 3.50 2.08 3.44 2.99 2.31 3.76 <0.001
SD 0.61 1.25 0.65 0.63 1.25 0.94 1.51 0.85 1.48 0.85 1.50 1.18 0.74 1.22
Plasma-dialysate K gradient mEq/liter
Mean 2.99 1.23 3.22 3.11 1.23 2.17 1.22 2.59 1.35 2.59 1.29 1.94 2.85 1.26 <0.001
si 1.02 0.48 0.94 0.98 0.48 0.73 0.67 1.21 0.64 1.21 0.66 0.94 1.10 0.57
differ during the first two hours, after which the difference
between them becomes very small.
We are well aware that the prognostic value of arrhythmias and
their treatment in arrhythmic patients is still a question of debate
[17—19], and a previous study of ours does not seem to support any
prognostic value of arrhythmias for mortality in HD patients [20].
Moreover, the impact of the problem on the general population of
regularly dialysed patients seems to be very low. Only 2% of our
recruited patients satisfied the entry criteria of the protocol
although it is known that the incidence of arrhythmia is generally
higher in the hemodialyzed population. This could lead to some
concerns as to the general applicability of our study in the dialysis
population as a whole. However, we would like to point out that
the effect of the treatment with this new model of HD potassium
removal is more evident for both variables in sequence 1 (which
included patients who were less arrhythmic before HD than those
in sequence 2). Although the patients were randomly assigned to
the treatments, the higher number of less arrhythmic patients in
sequence 1 makes it possible to see that the arrhythmogenic effect
of HD treatment can be detected more easily in the presence of
light rather than heavy cell damage; this is the tip of the iceberg of
the electrophysiological derangement induced by standard HD
treatment ("electrical disequilibrium syndrome"). As plasma urea
concentration is a marker of uremic toxicity, it is possible to
consider HD arrhythmias as a marker of the electrophysiological
status of the cells.
Although uremic patients usually already have a decreased
potassium pool [21, 22], in order to counterbalance the interdialy-
sis potassium load and avoid life-threatening hyperkalemia, po-
tassium is removed by HD. Unlike HD sodium removal, which
can even be exclusively convective [23, 24], HD potassium removal
is almost exclusively diffusive. It is therefore necessary to create a
gradient between plasma and dialysate potassium concentrations,
which means greatly reducing plasma potassium concentrations
during HD. However, very different amounts of potassium re-
moval can be obtained with quite small differences in the dialysate
plasma gradient since the potassium removal is mainly due to a
decrease in the intracellular potassium pool. Our studies on
dialytic potassium removal [25] show that the higher the plasma-
dialysate potassium gradient, the greater the potassium removal
from intracellular fluid. The uremia related inhibition of the Na-K
pump produces a potassium shift from intra- to extracellular fluid
and consequently induces hyperkalemia; thus, the more advanced
the cellular sickness, the bigger the cellular depauperation of
potassium during dialysis. Moreover the post-dialysis rebound of
kalemia, ten times higher than that of urea and lasting over five
hours [261, shows that the potassium loss from cells continues
after the end of dialysis. Consequently, there is a vicious circle:
although it improves the function of the Na-K pump, dialysis
treatment maintains and even increases cellular distress by reduc-
ing the intracellular potassium pool. Thus, in our opinion, the new
approach explored in this study seems to be particularly suitable
for patients prone to life-threatening hyperkaliemia.
It is known from physiology studies that the wholeness of the
cellular potassium pool is necessary to many cellular functions:
volume and pH regulation [27, 28]; the synthesis of structural
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Fig. 5. Plasma (upper panel), dialysate (middle
panel) and plasma-dialysate K gradient (lower
panel) concentrations at the start, after the first
hour and at the end of dialysis in sequence by
period groups. The intradialysis plasma-dialysate
K gradient concentration was constant during
treatment B (period 2 in sequence 1 and
periods 1 and 3 in sequence 2) and
exponentially decreased during treatment A
(periods 1 and 3 in sequence 1 and period 2 in
sequence 2). There was a specular trend for
dialysate K concentrations.
proteins [29], enzymes [30] and hormones [26]; glucose metabo-
lism [31], etc. The cachexia of hemodialyzed patients who undergo
thrice-weekly HD treatment over many years is, in our opinion, at
least partly the result of the vicious circle mentioned above.
In spite of the fact that studies on the body potassium pools of
chronic HD patients have found decreased values in comparison
with normal subjects [21, 22], it is difficult to define how much
potassium should be removed by HD. It is worth noting that
peritoneal dialysis removes much less potassium than HD [32],
that fecal potassium excretion may be up to 80% of dietary intake
in some HD patients [33, 34], and that in the integrated diet and
dialysis program with only once a week hemodialysis the incidence
of hyperkalemia is very low [35]. However, although it is our
opinion that intradialytic potassium removal may be too high,
there is a general reluctance to reduce it by reducing the
plasma-dialysate potassium gradient for fear of interdialytic hy-
perkalemia.
In the experimental procedure used in the present study, the
mean baseline dialysate potassium concentration was 1.45 mEq/
liter higher than during the standard procedure; consequently, we
would expect that dialytic potassium removal to be less. However,
the mean pre-HD plasma potassium values were similar after the
experimental and standard treatments (5.46 vs. 5.48 mEqlliter)
and the incidence of hyperkaliemia did not seem to be related to
the type of treatment. On the basis of our results, the experimen-
tal model appears to be clinically safe, although long-term studies
would be welcome.
In conclusion, the use of a new model of intra-HD potassium
removal by means of a reduction in the plasma-dialysate potas-
sium concentration gradient significantly decreased the arrhyth-
mogenic effect of HD in patients on regular HD treatment,
particularly during the first two hours. This result was obtained
without adversely affecting pre-dialysis plasma potassium levels in
comparison with the standard HD procedure. The results of this
study could have wider clinical implications than simply reducing
HD-related arrhythmias. The arrhythmogenic effect of HD may
Radaelli et al: Hemodialysis K removal and arrhythmias 617
be a marker of the electrophysiological derangement of the
excitable cells of uremic patients during hemodialysis that pro-
duces cell damage (electrical disequilibrium syndrome). In stan-
dard HD, the electrical disequilibrium syndrome occurs three
times a week for many years. Its reduction could have consider-
able clinical impact not only on acute intradialysis complications,
but also on the morbidity and mortality of patients on chronic
hemodialysis treatment. Moreover, the usually reduced body
potassium pool of uremic patients may be better preserved and
consequently the onset of cachexia may be hindered.
Reprint requests to Bruno Redaell4 M.D., Divisione di Nefrologia e Dialisi,
Ospedale "S. Gerardo," Via Solferino 16, 20052 Monza, Milan, Italy.
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